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Abstract 
Myelodysplastic syndrome with excess blasts 
(MDS-EB) represents the most clinically aggressive 
end of the continuum of the myelodysplastic 
syndromes (MDS). All MDS are characterized by 
clonal, ineffective hematopoiesis with maturation 
defects and increased apoptosis resulting in 
peripheral blood cytopenias, abnormal myeloid 
maturation (dysplasia) and variable risk of 
progression to bone marrow failure and/or acute 
myeloid leukemia. Progressive degrees of restricted 
myeloid maturation represented by abnormally 
increased numbers of morphologically-defined 
blasts in the blood and/or bone marrow is the key 
feature separating MDS-EB from the other 
myelodysplastic syndromes and is strongly 
associated with increased risk of disease progression 
and decreased survival. Metaphase chromosome 
analysis of bone marrow myeloid cells is the 
cornerstone of documenting clonal hematopoiesis to 
establish the diagnosis of MDS and for risk 
stratification of patients with confirmed MDS. 
Molecular analyses are becoming increasingly 
utilized for diagnosis and prognosis. 
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Identity 
Other names 
Refractory anemia with excess blasts (W.H.O. 2001, 
W.H.O. 2008, F.A.B. 1976, F.A.B 1982). 
Myelodysplastic syndrome with excess blasts is the 
W.H.O. 2016 s name. 
Clinics and pathology 
Disease 
Myelodysplastic syndrome with excess blasts 
(MDS-EB) is a clonal disorder of hematopoietic 
stem cells (HSC) characterized by morphologically 
disordered maturation ("dysplasia") and restricted 
maturation of the myeloid lineages in the bone 
marrow resulting in ineffective hematopoiesis, 
cytopenias, increased blasts (5-19% of blood or bone 
marrow nucleated cells), and increased risk of 
progressive bone marrow failure and/or developing 
acute myeloid leukemia. Disease-specific morbidity 
and mortality is related to cytopenias, i.e. anemia, 
neutropenia, and thrombocytopenia resulting in 
infection and/or bleeding, due to progressive bone 
marrow failure and/or development of acute 
leukemia. 
Phenotype/cell stem origin 
Recent work suggests that the leukemia stem cell in 
myelodysplastic syndromes is a specific 
hematopoietic stem cell with the following 
phenotype: Lin-, CD34+, CD38-, CD90+, and 
CD45RA- (Woll et al., 2014). 
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Epidemiology 
Myelodysplastic syndromes may affect individuals 
of any age, gender or ethnicity. Accurate 
measurement of the incidence of myelodysplastic 
syndromes, including MDS-EB, is very difficult to 
obtain due to underreporting and underdiagnosing, 
but clearly shows a marked increase incidence with 
age. Some estimates are as high as 63.9 / 100,000 in 
people ≥85 y.o. (Cogle et al., 2015). The median age 
of diagnosis is around 71 years (Pfeilstöcker et al., 
2016). 
Clinics 
Patients may present with asymptomatics cytopenias 
identified on routine laboratory testing or due to 
symptoms related to cytopenias, e.g. fatigue or 
exercise intolerance due to anemia, infections due to 
neutropenia and/or bleeding due to 
thrombocytopenia. Diagnosis requires examination 
of blood and bone marrow for morphological 
features of disordered maturation of myeloid 
lineages ("dysplasia") and enumeration of blast cells 
in blood and marrow correlated with genetic and 
often molecular testing. 
 
Bone marrow aspirate smear from a patient with MDS-EB (Wright-Geimsa, 1000X). A. Extensive 
dysgranulopoiesis with marked nuclear-to-cytoplasmic dyssynchrony, numerous "Pelgeroid" segmented 
neutrophils with bilobed nuclei and hypogranular cytoplasm (∗) and giant forms. B. Increased blasts (arrows). 
 
Cytogenetics 
Metaphase chromosome analysis remains a crucial 
pillar in the diagnosis and prognosis of patients with 
MDS. Overall, about 40-50% of all individuals with 
de novo MDS will show a clonal chromosomal 
abnormality at the time of diagnosis (Greenberg 
2012). Not surprisingly, the likelihood of identifying 
a clonal chromosomal abnormality is correlated with 
the severity of the disease, e.g. about 32 %patient's 
with MDS with single-lineage dysplasia and 
Chromosomal abnormalities in myelodysplastic 
syndromes are myriad, but the most common are 
unbalanced resulting in net loss/gain of 
chromosomal material, such as monosomy, deletions 
and/or unbalanced translocations, and trisomy. 
Specifically, the incidence of common chromosomal 
abnormalities in MDS with an abnormal karyotype 
is: del(5q) (30%), -7/del(7q) (21%), +8 (16%), -
18/18q- (7%), 20q- (7%), -5 (6%), -Y (5%), -17/17p- 
(including isochromosome (17q)) (5%), +Mar (5%), 
+21 (4%), inv/t(3q) (4%), -13/13q- ID: 1096 (4%), 
+1/+1q (3%), -21 (3%), +11 (3%), 12p- (2%), t(5q) 
(2%), 11q- (2%), and t(7q) (2%). MDS-EB is 
enriched for unfavorable risk abnormalities (i.e. ≥ 3 
abnormalities or any chromosome 7 abnormality) as 
compared to MDS with <5% blasts. (Haase 2017)    
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The most recent multinational study of prognosis in 
MDS created a Revised International Prognostic 
Scoring System (IPSS-R) (Greenberg et al.,2012) 
stratified chromosomal abnormalities into 5 
categories:  Very good, good, intermediate, poor and 
very poor as follows: (Schanz et al, 2012). 
 
In contrast to acute myeloid leukemia (AML), 
balanced reciprocal translocations are conspicuously 
uncommon in MDS-EB. 
 
IPSS-R Cytogenetic Risk Categories 
Very Good: Single: del(11q), -Y 
Good: Single: Normal, del(5q), del(12p), del(20q) 
 Double: including del(5q) 
Intermediate: Single: del(7q), +8, i(17q), +19, any other, independent clones 
 Double: any other 
Poor: Single: inv(3)/t(3q)/del(3q) 
 Double: including -7/del(7q) 
 Complex: 3 abnormalities 
Very poor: Complex: Greater than 3 abnormalities 
 
I. 
Genes 
As about 40% of patients with MDS-EB will have 
normal metaphase chromosomes, many 
investigators have sought to use higher-resolution 
molecular techniques to identify diagnostic, 
prognostic and predictive molecular aberrations. 
The use of FISH for as an adjunct to metaphase 
chromosome analysis in MDS is controversial. 
Many physicians routinely request a panel of 
interphase FISH probes to common and/or clinically 
significant abnormalities (e.g. -5/5q-, +8, -7/7q-, 
20q-, 17p/TP53) a priori for all patients with 
suspected or confirmed MDS. However, several 
studies have shown essentially no additional 
clinically useful information is discovered with this 
technique if the metaphase study is adequate. 
Interphase FISH may be useful for specimens 
without adequate metaphases. Metaphase and/or 
interphase FISH may also be helpful to clarify subtle 
abnormalities of metaphase spreads. 
Array comparative genomic hybridization (aCGH) 
and single nucleotide polymorphism array (SNP 
array) are particularly attractive methods to 
interrogate the entire genome at a fairly fine 
resolution to identify the gains and/or losses of 
chromosomal material that are common in MDS. 
Additionally, SNP arrays can identify copy-neutral 
loss of heterozygosity (CN-LAH) which can 
functionally inactivate tumor suppressor genes, 
similar to gross monosomies and deletions. These 
techniques have been shown to confirm most, but not 
all chromosomal abnormalities concurrently 
identified in metaphase chromosome analysis. They 
also detect additional abnormalities in genes or 
regions implicated in the pathogenesis or prognosis 
of patients with myeloid neoplasia. The precise 
clinical significance of detecting these 
submicroscopic chromosomal abnormalities in 
patients with MDS is currently under extensive 
study. 
Sequence level techniques, including targeted 
sequencing of specific genes or broader whole-
genome sequencing (WGS) may be used to 
document clonal hematopoiesis and to provide 
prognostic and predictive data to patients with 
established MDS. Targeted sequencing techniques 
will identify mutations in up to 90% of all MDS 
patients. Commonly mutated genes include: SF3B1, 
TET2, SRSF2, ASXL1, DNMT3A, RUNX1, 
U2AF1, TP53, and EZH2 (Haferlach et al., 2014). 
The clinical significance of specific mutations is 
currently evolving (Bejar et al, 2017). 
In patients with MDS-EB, the issue of clonality is 
rarely a question, but the predictive information 
about which therapies may work for an individual 
patient may prove highly beneficial, such as 
mutations of IDH1 /IDH2 that can be targeted by 
specific drug therapies. In addition, these techniques 
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have identified novel genetic abnormalities and 
mechanisms, e.g. chromothripsis, which are 
improving our understanding of the mechanisms of 
disease development and progression (Abaigar et al., 
2016). 
Treatment 
Treatment options for patients with MDS-EB 
include a broad spectrum of options from supportive 
care, low-intensity therapies, to high-intensity 
therapies +/- stem cell transplantation. Given that the 
incidence of MDS-EB is highly positively correlated 
with age, it is no surprise that many patients will 
have significant comorbidities and decreased 
performance status at the time of diagnosis, which 
are likely to limit their tolerance of higher-intensity 
chemotherapy and stem cell transplant. 
Supportive care options are aimed at ameliorating or 
lessening symptoms and improving quality of life, 
such as RBC transfusion to improve symptoms of 
decreased oxygen carrying capacity or platelet 
transfusions for bleeding events. Antifibrinolytics 
may benefit patients who are unresponsive to platelet 
transfusion. Some patients may also respond to 
colony stimulating factors such as erythropoietin, 
granulocyte colony stimulating factor, granulocyte-
monocyte stimulating factor and thrombopoietin 
mimetics. 
Low intensity therapeutic options mostly center 
hypomethylating agents such as 5' azacytidine or 
decitabine or low-dose cytotoxic chemotherapies 
such a as cytosine arabinoside. Some patients will 
respond to immunosuppression (ATG) and/or 
biological response modifiers (lenalidomide) 
suggesting an immune-mediated etiology in some 
individuals. 
High intensity treatments are similar to those used 
for acute myeloid leukemia such as intensive 
induction chemotherapy, e.g. 
idarubicin/daunorubicin, cytarabine/fludarabine, 
topoisomerase inhibitors, etc. +/- allogeneic stem 
cell transplantation. 
Evolution 
MDS-EB is usually a clinically and genomically 
unstable disease state with a very high rate of 
progression to death due to bone marrow failure 
and/or acute myeloid leukemia (>20% blasts). 
Cytogenetic evolution often accompanies and/or 
precedes clinical and morphological progression. 
Prognosis 
The prognosis for patients with MDS has been 
studied intensively leading to several risk 
stratification models, e.g. IPSS, IPSS-R and IPSS-
RA (ie, IPSS-R including age),the original WHO 
classification-based Prognostic Scoring System 
(WPSS) applying transfusion need, its modification 
using hemoglobin thresholds (WPSS 2011) and its 
modification including age (WPSS-A), and the 
Lower-Risk Prognostic Scoring System (LR-PSS). 
(Pfeilstoeker et al., 2016) The most commonly used 
system in clinical practice is the IPSS-RA. 
(Greenberg et al, 2012) These systems all 
incorporate chromosomal analysis with clinical and 
morphological features. Most patients with MDS-EB 
will be stratified into higher-risk categories with 
median overall survival about 9 months to 2 years 
and about 50-90% risk of progression to AML within 
5 years. 
Cytogenetics 
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Abnormal karyogram from the bone marrow of a patient with MDS-EB showing a highly complex karyotype 
with numerous monosomies and unbalanced translocations resulting in net loss of chromosomal material. 
Common abnormalities associated with MDS include del(5q), -7q, del(17p), -18, -20 are illustrated. Karyogram 
and interpretation provided by Rhett P. Ketterling, M.D., Mayo Medical Laboratories, Rochester, MN, USA. 
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